RT Journal Article
SR Electronic
T1 Long-lasting cellular immunity to SARS-CoV-2 following infection or vaccination and implications for booster strategies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.29.21268469
DO 10.1101/2021.12.29.21268469
A1 Mazzoni, Alessio
A1 Vanni, Anna
A1 Spinicci, Michele
A1 Lamacchia, Giulia
A1 Kiros, Seble Tekle
A1 Rocca, Arianna
A1 Capone, Manuela
A1 Di Lauria, Nicoletta
A1 Salvati, Lorenzo
A1 Carnasciali, Alberto
A1 Mantengoli, Elisabetta
A1 Farahvachi, Parham
A1 Zammarchi, Lorenzo
A1 Lagi, Filippo
A1 Colao, Maria Grazia
A1 Liotta, Francesco
A1 Cosmi, Lorenzo
A1 Maggi, Laura
A1 Bartoloni, Alessandro
A1 Rossolini, Gian Maria
A1 Annunziato, Francesco
YR 2021
UL http://medrxiv.org/content/early/2021/12/31/2021.12.29.21268469.abstract
AB Immunization against SARS-CoV-2, the causative agent of coronavirus disease-19 (COVID-19) occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last. We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 following mRNA vaccination in naïve and COVID-19 recovered individuals. We found that cellular immunity is still detectable 8 months after vaccination, while antibody levels decline significantly especially in naïve subjects. We also found that a booster injection is more efficacious in reactivating immunological memory to spike protein in naïve than in previously SARS-CoV-2 infected subjects. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to one year following natural infection in a cohort of unvaccinated individuals. Short-term persistence of humoral immunity may account for reinfections and breakthrough infections, although long-lived memory B and CD4+ T cells may protect from severe disease. A booster dose restores optimal anti-spike immunity in naïve subjects, while the need for vaccinated COVID-19 recovered subjects has yet to be defined.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018-2022), by the University of Florence, project RICTD2122, by the Italian Ministry of Health (COVID-2020-12371849) and by Tuscany Region (TagSARS CoV 2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Area Vasta Toscana Centro gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript